A comparative study of policosanol versus probucol in patients with hypercholesterolemia

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 1, 1997, Pages 26-35

  Pons, Pedro ^a   Illnait, José ^a   Más, Rosa ^a   Rodríguez, Mirta ^a   Alemán, Celia ^a   Fernández, Julio César ^a   Fernández, Lilia ^a   Martin, Mirta ^b  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b HOSPITAL UNIVERSITARIO GENERAL CALIXTO GARCÍA   (Cuba)

Author keywords

hypercholesterolemia; policosanol; probucol

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; PROBUCOL; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPNEA; FEMALE; FLATULENCE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; INSOMNIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VOMITING;

EID: 0031019054     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80074-4     Document Type: Article

References (50)

1. Stamler J, Wentworth D, Neaton JD, for the Multiple Risk Factor Intervention Trial Research Group. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenings of the Multiple Risk Factor Intervention Trial. JAMA. 1986;256:2823.
2. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in the incidence of coronary heart disease. JAMA. 1984;251: 351-364.
3. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in the incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
4. Frick MH, Elo D, Haapa K, et al. Helsinki Heart Study: Primary-intervention trial with gemfibrozil in middle-aged men with dislipidemia. NEJM. 1987;317:1237-1245.
5. O'Connor P, Feely J, Shepherd J. Lipid lowering drugs. BMJ. 1990;300:667-672.
6. Tikkanen MJ, Nikkila EA. Current pharmacologic treatment of elevated serum cholesterol. Circulation. 1987;76:529-533.
7. Oelbaum RS, Galton DJ. Management of hypercholesterolaemia. Curr Opinion Cardiol. 1988;3:255-263.
8. Tobert JA. New developments in lipid-lowering therapy: The role of inhibitors of hydroxymethyl-glutaryl-coenzyme A reductase. Circulation. 1987;76:534-538.
9. Sirtori CR, Manzoni C, Lovati MR. Mechanisms of lipid-lowering agents. Cardiology. 1991;78:226-235.
10. Boccuzzi SJ, Keegan ME, Hirsch LJ, et al. Long term experience with simvastatin. Drug Invest. 1993;5:135-140.
11. Steiner A, Weisser B, Vetter W. A comparative study of the adverse effects of treatments for hyperlipidaemia. Drug Safety. 1991;6:118-130.
12. O'Connor O, Feely J, Shepherd J. Lipid lowering drugs. BMJ. 1990;300:667-672.
13. Arruzazabala ML, Carbajal D, Más R, et al. Cholesterol-lowering effects of policosanol in rabbits. Biol Res. 1994;27:205-208.
14. Rodríguez C, Mesa R, Más R, et al. Estudio del efecto sobre lípidos y lipoproteínas séricos y de la tolerancia al tratamiento oral con dosis crecientes de policosanol en monos (Macaca arctoides). Arch Venez Farmacol Ter. 1992;11:74-79.
15. Hernández F, Illnait J, Más R, et al. Effect of Ateromixol (policosanol) on serum lipids and lipoproteins in healthy volunteers. Curr Ther Res. 1992;51:1-8.
16. Castaño G, Zardoya R, Illnait J, et al. Efectos del tratamiento con Ateromixol (PPG) (5 mg) en pacientes con hiperlipoproteinemia tipo II. PCM. 1991;5:21-28.
17. Soltero I, Fuenmayor I y Colmenares J. Estudio comparativo doble ciego de la eficacia y tolerancia del policosanol vs bezafibrato en pacientes con hiperlipidemias tipo II. Arch Venez Farmacol Ter. 1993;12:71-76.
18. Aneiros E, Calderón B, Más R, et al. Effects of successive dose increases of policosanol on the lipid profile and tolerability of treatment. Curr Ther Res. 1993;54:304-312.
19. Pons P, Rodríguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. J Clin Pharmacol Res. 1994;14:27-33.
20. Pons P, Rodríguez M, Más R, et al. One year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res. 1994;55:1084-1092.
21. Aneiros E, Más R, Calderón B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res. 1995;56:176-182.
22. Castaño G, Más R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res. 1995;56:296-304.
23. Canetti M, Moreira M, Illnait J, et al. One year study on the effect of policosanol (5 mg twice-a-day) on lipid profile in patients with type II hypercholesterolemia. Ad Ther. In press.
24. Canetti M, Moreira M, Illnait J, et al. A two year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinemia. Int J Clin Pharmacol Res. In press.
25. Pons P, Jiménez A, Rodríguez M, et al. Effects of policosanol in elderly hypercholesterolemic patients. Curr Ther Res. 1993;53:265-269.
26. Castaño G, Canetti M, Moreira M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hyperlipoproteinemia: A 12-month study. Curr Ther Res. 1995;56: 819-828.
27. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995;18:393-397.
28. Menéndez R, Fernandez I, del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res. 1994;27:199-203.
29. Alemán CL, Rodeiro I, Noa M, et al. Acute, subchronical and chronic toxicity of policosanol in rats. Presented at the Sixth International Congress of Toxicology, Rome, June 28-July 3, 1992:248.
30. Alemán CL, Más R, Hernández C, et al. A 12 month study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett. 1994;70:77-87.
31. Mesa A del R, Más R, Noa M, et al. Toxicity of policosanol in Beagle dogs: One year study. Toxicol Lett. 1994;73:81-90.
32. Rodríguez C, Mesa R, Más R, et al. Effect of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem Toxicol. 1994;32:565-575.
33. Alemán CL, Más R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study. Teratog Carcinog Mutag. 1994;14:239-249.
34. Buckley MM, Karen L, Goa A, Price AH, Brodgen RN. Probucol: A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolemia. Drugs. 1989; 37:761-800.
35. Dujovne CA, Krehbiel P, Chernoff SB. Controlled studies of the efficacy and safety of combined probucol-colestipol therapy. Am J Cardiol. 1986;57:36H-42H.
36. Durrington PN, Miller JP. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia. Atherosclerosis. 1985;55:187-194.
37. Enjalbert M, Lussier-Cacan S, DuBreuil-Quidoz S, et al. Usefulness of probucol in treating primary hypercholesterolemia. Can Med Assoc J. 1980;123:754-757.
38. Fellin R, Gasparotto A, Valerio G, et al. Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia. Atherosclerosis. 1986;59:47-56.
39. Rouffy J, Bakir R, Chanu B, et al. Probucol: An evaluation of effects on plasma lipids and lipoproteins in 34 cases of primary types IIa and IIb hyperlipoproteinemia. In: Noseda, et al, eds. Diet and Drugs in Atherosclerosis. New York: Raven Press; 1980:237-244.
40. Beaumont V, Buxtorf JC, Jacotot B, Beaumont JL. Short- and long-term trials of probucol in type II hyperlipoproteinemia. In: Noseda, et al, eds. Diet and Drugs in Atherosclerosis. New York: Raven Press; 1980:209-214.
41. Boyden TW, Totman L. Synergistic effects of probucol and cholestyramine to lower serum cholesterol. J Clin Pharmacol. 1981;21:48-51.
42. The Lovastatin Study Group IV. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. Am J Cardiol. 1990;66:22B-30B.
43. Davignon J, Xhignesse M, Mailoux H, et al. Comparative study of lovastatin versus probucol in the treatment of hypercholesterolemia. Atherosclerosis Reviews. 1988;18: 139-151.
44. Ikeda T, Ochi H, Ohtani I, et al. Comparison of the effects of small doses of probucol and pravastatin on serum lipids and apolipoproteins in nonobese, non-insulin-dependent diabetes mellitus patients with hypercholesterolemia. Curr Ther Res. 1992;51:593-599.
45. Cristol LS, Jialal I, Grundy SM. Effect of low-dose therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers. Atherosclerosis. 1992;97:11-20.
46. Paterson JR, Rumley AG, Oldroyd KG, et al. Probucol reduces plasma lipid peroxides in man. Atherosclerosis. 1992;97:63-66.
47. Regnstrom J, Walldius G, Carlson LA, Nilsson J. Effect of probucol treatmnt on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro. Atherosclerosis. 1990;82:43-51.
48. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem. 1981;27:838-841.
49. Friedewald WT, Levy RI, Friederickson SD. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
50. Illingworth DR. An overview of lipid lowering drugs. Drugs. 1988;36(Suppl 3):63-71.